25 Disruptive Technology Startups Join Morgan Stanley Inclusive Ventures Lab’s 10th Cohort
Morgan Stanley (NYSE: MS) today announced the 2024 global cohort of the Inclusive Ventures Lab, with 25 companies selected from the Americas and Europe, the Middle East and Africa (EMEA). Over the next five months, the companies will participate in an in-house accelerator program designed to further develop and scale technology and technology-enabled startups in the seed to Series A funding round stage.
Chosen from thousands of applications, the 25 startups represent a range of disruptive technologies across industries such as Climate Tech, Retail, Healthcare, FinTech, SaaS, Enterprise Software, Consumer and Travel – with many incorporating AI and sustainability into their products and services. Cohort companies will receive a $250,000 investment (£250,000 in EMEA) from Morgan Stanley, as well as a variety of mentorship opportunities, a tailored entrepreneurship curriculum and business-growth resources from the firm’s ecosystem of internal and external partners.
“In today’s challenging venture capital environment, we are proud to welcome our largest cohort of groundbreaking startups to the Inclusive Ventures Lab and are eager to support them as they scale their innovations and work to build a better world,” said Selma Bueno, Global Head of the Morgan Stanley Inclusive Ventures Group. “Each year since the Inclusive Ventures Lab’s launch in 2017, we have expanded our efforts to ensure that more entrepreneurs around the world can succeed – and this year is no different.”
The companies selected to participate in the 2024 cohort include the following:
- Agri-Trak digitizes small farm operations with a smart platform for real-time labor, crop yield and cost tracking to optimize productivity, sustainability and profitability (US)
- Beta Financial provides a transparent and comprehensive small business credit scoring solution, fostering financial inclusion and access to capital through innovative AI-driven technology (US)
- Blip Energy is building a drop-in distributed energy resource to mitigate surging peak demand, optimize energy costs for users and reduce operating costs for utilities (US)
- Compare Ethics is an AI-powered sustainability compliance platform that reduces costs by helping retail brands simplify, streamline and scale the way they make accurate green claims (UK)
- Darent is a vacation rental marketplace platform in Saudi Arabia for travelers to search for properties with a focus on local experiences, a secure payment system and property insurance for hosts (Saudi Arabia)
- For The Creators is an omni-channel circular fashion marketplace where women can rent and buy high-quality clothing for each stage of motherhood (UK)
- GroceryList is a marketplace connecting immigrants worldwide with local merchants across Latin America and the Caribbean, enabling them to purchase groceries and essentials for their loved ones back home (US)
- HANX is a consumer platform bringing together medically designed women’s reproductive health products, prescription treatments and community-focused content (UK)
- Hire Ground is a B2B software platform that enables enterprise buyers to source and manage third party vendors while optimizing their procurement process (US)
- Infinite Giving is a fintech platform that enables nonprofits to raise money, manage their cash reserves, and conservatively invest and grow (US)
- Juniver is a health company leveraging AI technology to provide personalized digital interventions for lasting eating disorder recovery (UK)
- KSI Vision uses existing AI on store and shopping center security cameras to generate real-time customer data and increase sales conversion (Uruguay)
- Mavity is an AI-powered operating system for design and marketing teams that connects companies with on-demand creatives to streamline asset creation (US)
- MyARC is a platform that enables fitness content creators to train their fans at scale (UK)
- NÜWIEL provides electric mobility solutions for the cities of today and tomorrow (Germany)
- OVUM is a one-stop shop for fertility wellness, providing educational resources, products and services for improving fertility outcomes (UK)
- Research Grid is an automation engine for admin-free clinical trials (UK)
- Revere is reinventing how allocators manage their alternative asset portfolios through AI, workflow automation tools and custom reporting (US)
- Route is a platform of business management tools for commercial cleaning companies to automate sales, streamline operations, build contractor relationships and connect the entire cleaning industry (US)
- Sanarai connects the Latino community to mental health professionals in Latin America and the US to offer culturally sensitive, Spanish-language emotional support at accessible prices (US)
- Soralink leverages AI and smart sensors to assist manufacturers in preventing critical machine failures (Canada)
- Sortile provides the textile industry with a system that enables the identification, traceability and recycling of textiles (US)
- SWYE360 Learning is a data analytics company that uses machine learning and AI in education to measure software efficacy and detect students at risk of dropping out (US)
- Tendo Technologies addresses the challenges faced by aspiring online retail entrepreneurs in Africa by connecting independent resellers to suppliers (Ghana)
- Zest Equity is digitizing private market transactions, building tools to streamline and ensure greater transparency in how entrepreneurs, funds and investors transact (UAE)
Programming will culminate in February 2025 with a global Demo Day, when participating companies will present to potential investors, business partners and customers. The investment firms in attendance at the last showcase represented over $40 billion of dry powder and indicated a high level of interest following the event.
About the Morgan Stanley Inclusive Ventures Lab
The Morgan Stanley Inclusive Ventures Lab (MSIVL) is an intensive five-month in-house accelerator program designed to help further develop and scale startups, culminating in a showcase presentation and Demo Day to the investor community. Morgan Stanley launched MSIVL, formerly called the Multicultural Innovation Lab, in 2017 in order to address inequities in funding of startup founders, which our research shows equals over four trillion dollars in unrealized returns.
About Morgan Stanley
Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm’s employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit www.morganstanley.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240913405364/en/
Contacts
Media Relations Contact:
Carrie Hall
Carrie.Hall@morganstanley.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kweichow Moutai’s Brand Culture Activities in Greece Foster Sino-Greek Cultural Cooperation21.12.2024 19:41:00 CET | Press Release
On December 9th, the exhibition “Longevity in the Tao of Chrysanthemum: The Artistic World of Qi Baishi,” supported by Kweichow Moutai Group, opened at the Athens University History Museum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241221429801/en/ Gao Shan(R3), and Petros Tatoulis(R2), took a group photo with other guests at the opening ceremony of the exhibition. (Photo: Business Wire) Featuring the works of Qi Baishi, a renowned Chinese painter, the exhibition highlights the unique charm of traditional Chinese culture for Western audiences, while advancing cultural exchange and mutual understanding between China and Greece. Gao Shan, Chairman of the Labor Union at Kweichow Moutai Distillery (Group) Co., Ltd., remarked on the significance of the event, saying, “Qi Baishi employed distinctive Eastern painting techniques to convey the Chinese perspective of the world. Athens, a city celebrated for its great masters and
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom